Solid Bioscience SEC Filings

Solid Biosciences Inc. files a registration statement to register the resale of 1,316,899 shares of its common stock on behalf of selling stockholder FA212 LLC. The shares were issued in private placements under an Asset Purchase Agreement, and the company will receive no proceeds from resales.

The registration covers resale by FA212 LLC of shares issued on January 15, 2026 following dosing in a Phase 1b trial of SGT-212. The prospectus states the selling stockholder may sell shares in public or private transactions, and Solid will bear registration expenses while FA212 LLC will pay sales-related fees.

Solid Biosciences is a gene therapy company focused on rare neuromuscular and cardiac diseases. Its lead program, SGT-003 for Duchenne muscular dystrophy, is in a Phase 1/2 trial with generally well-tolerated dosing in 41 participants and strong microdystrophin expression and biomarker improvements. A global Phase 3 trial in ambulant boys aged 7 to under 12 is starting, with potential accelerated approval discussions planned.

The company is also advancing SGT-212 for Friedreich’s ataxia in a Phase 1b dual-route (brain and IV) study, and SGT-501 for catecholaminergic polymorphic ventricular tachycardia in a Phase 1b trial. Preclinical cardiac candidate SGT-601 targets TNNT2-mediated dilated cardiomyopathy. Solid is building a broad platform around its POLARIS‑101 capsid, next‑generation capsid libraries, and manufacturing partnerships, supported by multiple licenses and collaborations with leading academic centers.

RA Capital Management and affiliates filed Amendment No. 12 to their Schedule 13D on Solid Biosciences Inc., reporting beneficial ownership of 9,313,756 shares of common stock, representing 9.9% of the class. The position includes shares held by RA Capital Healthcare Fund, RA Capital Nexus Fund, a separately managed account, and pre-funded warrants exercisable for up to 8,178,412 shares, subject to a 9.99% beneficial ownership blocker.

In March 2026, the Fund made a series of open-market purchases: 615,259 shares on March 11 at a weighted-average price of $7.28 per share for an aggregate of $4,480,927.77, 302,081 shares on March 12 at $7.66 per share for $2,314,394.77, 691,702 shares on March 13 at $7.32 per share for $5,063,619.06, 1,052,072 shares on March 16 at $7.61 per share for $8,002,475.20, and 493,917 shares on March 17 at $7.79 per share for $3,848,700.05, all funded with the Fund’s working capital.

Solid Biosciences Inc. reported positive new interim results from its Phase 1/2 INSPIRE DUCHENNE trial of gene therapy SGT-003 in pediatric Duchenne muscular dystrophy. As of the February 23, 2026 cutoff, 40 participants had been dosed at 1E14 vg/kg, with SGT-003 generally well tolerated under a steroid-only prophylactic regimen.

Muscle biopsies in 20 participants at Day 90 and 3 at Day 360 showed robust microdystrophin expression, with mean western blot levels of 60% and 91% of normal and strong beta-sarcoglycan and nNOS localization. Serum biomarkers of muscle damage such as CK, ALT, AST and LDH showed 30–46% mean reductions at Day 90 and sustained improvements at Day 360, consistent with better muscle integrity.

The company also highlighted stabilization-to-improvement in cardiac systolic function by left ventricular ejection fraction, particularly in participants with low-normal baseline values. Solid Biosciences has reached FDA alignment on the randomized, double‑blind, placebo‑controlled Phase 3 IMPACT DUCHENNE trial and expects first dosing in the first quarter of 2026, with additional regulatory and clinical updates planned for mid‑2026, including discussions on a potential accelerated approval pathway for SGT-003.

Solid Biosciences Inc. received a large investment from funds managed by Perceptive. Perceptive Advisors LLC, Joseph Edelman and affiliated funds now report beneficial ownership of 11,969,079 shares of Common Stock, representing 12.9% of 92,883,496 shares outstanding.

Perceptive Life Sciences Master Fund acquired 8,912,655 pre-funded warrants in a private placement at $5.609 per warrant, for an aggregate purchase price of $49.9 million. These pre-funded warrants cannot be exercised if doing so would push Perceptive’s beneficial ownership above 9.99% of Solid’s outstanding shares, so they are not currently exercisable.

The ownership calculation combines shares outstanding as of October 29, 2025 with additional shares issued in the March 9, 2026 private placement. Adam Stone, the Advisor’s Chief Investment Officer, also holds options on 139,933 shares, with 62,433 currently exercisable or exercisable within 60 days.

Solid Biosciences Inc. reported that entities associated with Perceptive Advisors received a grant of pre-funded warrants to acquire 8,912,655 shares of Common Stock. These pre-funded warrants carry a de minimis exercise price of $0.001 per share and were acquired at $5.609 per warrant.

The warrants are directly held by Perceptive Life Sciences Master Fund Ltd., with Perceptive Advisors LLC serving as its investment manager and Joseph Edelman as managing member of the Advisor. The warrants do not expire and are subject to a 9.99% Beneficial Ownership Limitation on exercise. The reporting persons disclaim beneficial ownership beyond any indirect pecuniary interest.

Solid Biosciences Inc. and Bain Capital Life Sciences entities updated their ownership disclosure following a new private financing. The issuer completed a March 2026 private placement of 14,973,257 common shares at $5.61 per share and pre-funded warrants for 27,807,482 shares at $5.609 per warrant. Bain Capital Life Sciences Opportunities IV, L.P. bought a pre-funded warrant for 5,347,593 shares for $29,994,649.14, using its own working capital.

Across related Bain Capital Life Sciences funds, the group reports collective beneficial ownership of 9,808,819 shares of common stock, or 9.99% of the class, after applying 9.99% beneficial ownership blockers on pre-funded warrant exercises. Individual reporting entities show stakes ranging from 0.1% to 8.8% of the outstanding common stock.

RA Capital Management and affiliated funds report beneficial ownership of 9,663,926 shares of Solid Biosciences common stock, representing 9.9% of the class. The position is held through RA Capital Healthcare Fund, the RA Capital Nexus Fund, a managed account and pre-funded warrants.

In February 2026, the healthcare fund bought 354,936 shares in open-market trades at a weighted average price of $6.49 per share for total consideration of $2,304,350.99. On March 6, 2026, it also acquired 4,456,327 pre-funded warrants in a private placement for $24,995,538, each exercisable at $0.001 per share but capped by a 9.99% beneficial ownership blocker.

The March 2026 private placement issued 14,973,257 new shares and 27,807,482 additional pre-funded warrants to institutional investors. Solid Biosciences agreed in a registration rights agreement to register for resale the new shares and the common stock underlying the March 2026 pre-funded warrants.

Solid Biosciences Inc. entered into a private placement with institutional investors to sell 14,973,257 common shares at $5.61 per share and pre-funded warrants for 27,807,482 shares at $5.609 per warrant, for expected gross proceeds of about $240.0 million and net proceeds of about $226.8 million.

The company expects to report preliminary cash, cash equivalents and available-for-sale securities of roughly $187.9 million as of December 31, 2025, and believes its cash plus net placement proceeds can fund operations into the first half of 2028. Pre-funded warrants are immediately exercisable at $0.001 per share and are subject to beneficial ownership limits of 4.99% or 9.99%, up to a maximum of 19.99%. The company agreed to register the resale of all securities issued and to pay liquidated damages of 1.0% of each investor’s amount per 30-day period if specified registration deadlines are not met.